Association between color doppler vascularity index, angiogenesis-related molecules, and clinical outcomes in gastric cancer

Journal of Surgical Oncology

Volumn 99, Issue 7, 2009, Pages 402-408

  Chen, Chiung Nien ^a,c,d   Lin, Jen Jen ^b,c   Lee, Hsinyu ^c   Cheng, Yung Ming ^a   Chang, King Jen ^a,c   Hsieh, Fon Jou ^c   Lai, Hong Shiee ^a   Chang, Chien Cheng ^c,d   Lee, Po Huang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MING CHUAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

Author keywords

Angiogenesis; Color Doppler ultrasound; Gastric cancer; Microvessel density; Survival

Indexed keywords

CALRETICULIN; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CLASSIFICATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 66349099080     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21193     Document Type: Article

References (45)

1. Coleman MP, Esteve J, Damiecki P, et al.: Trends in cancer incidence and mortality. IARC Scientific Publications No. 121. Lyon, France: IARC; 1993; pp. 193-224.
2. Cancer incidence in Taiwan. Taiwanese Cancer Registry, Taipei 2006.
3. Wanebo HJ, Kennedy BJ, Chemiel J, et al.: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-592.
4. Kelsen DP: Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996;23:379-387.
5. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 1990; 4-6.
6. Sund M, Zeisberg M, Kalluri R: Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: Basic science to clinical application. Gastroenterology 2005;129:2076-2091. (Pubitemid 41772982)
7. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027. (Pubitemid 46202320)
8. Takahashi Y, Kitadai Y, Bucana CD, et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
9. Tanigawa N, Amaya H, Matsumura M, et al.: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15:826-832. (Pubitemid 27074254)
10. Khaliq A, Dunk C, Jiang J, et al.: Hypoxia down-regulates placenta growth factor (PlGF) while fetal growth restriction upregulates PlGF expression: Molecular evidence for placental hyperoxia in IURG. Lab Invest 1999;79:151-170.
11. Failla CM, Odorisio T, Cianfarani F, et al.: Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 2000;115:388-395.
12. Lacal PM, Failla CM, Pagani E, et al.: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000;115:1000-1007. (Pubitemid 32037443)
13. Takahashi A, Sasaki H, Kim SJ, et al.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-4237. (Pubitemid 24258135)
14. Kodama J, Seki N, Tokumo K, et al.: Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma. Eur J Gynecol Oncol 1997;18:508-510. (Pubitemid 27519422)
15. Crofford LJ: COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997;24:15-19. (Pubitemid 27314722)
16. Tsujii M, Kawano S, Tsuji S, et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716. (Pubitemid 28257578)
17. Ambs S, Merriam WG, Bennett WP, et al.: Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998;58:334-341. (Pubitemid 28047076)
18. Gallo O, Masini E, Morbidelli L, et al.: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-596. (Pubitemid 28204802)
19. Marrogi AJ, Travis WD, Welsh JA, et al.: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-4744. (Pubitemid 32110413)
20. Nathan C, Xie QW: Nitric oxide synthases: Roles, tolls, and controls. Cell 1994;78:915-918. (Pubitemid 24292319)
21. Lala PK, Chakraborty C: Role of nitric oxide in carcinognesis and tumor progression. Lancet Oncol 2001;3:149-156. (Pubitemid 33585926)
22. Johnson S, Michalak M, Opas M, et al.: The ins and outs of calreticulin: From the ER lumen to the extracellular space. Trends Cell Biol 2001;11:122-129. (Pubitemid 32289442)
23. Pike SE, Yao L, Jones KD, et al.: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-2356. (Pubitemid 29028507)
24. Dock W, Grabenwoger F, Metz V, et al.: Tumor vascularization: Assessment with duplex sonography. Radiology 1991;181:241-244.
25. Taylor KJW, Ramos I, Carter D, et al.: Correlation of Doppler US tumor signals with neovascular morphologic features. Radiology 1988;166:57-62. (Pubitemid 18027044)
26. Wu CH, Hsu MM, Chang YL, et al.: Vascular pathology of malignant cervical lymphadenopathy. Cancer 1998;83:1189-1196.
27. Cheng WF, Lee CN, Chu JS, et al.: Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. Cancer 1999;85:651-657. (Pubitemid 29075286)
28. Lassau N, Lamuraglia M, Koscielny S, et al.: Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of primary cutaneous melanomas: Correlation with recurrence after a 5 year follow-up period. Cancer Imaging 2006;6:24-29.
29. Chen CN, Cheng YM, Lin MT, et al.: Association of color Doppler vacularity index and microvessel density with survival in patients with gastric cancer. Ann Surg 2002;235:512-518. (Pubitemid 34258350)
30. Chen CN, Cheng YM, Liang JT, et al.: Color Doppler vascularity index can predict distant metstasis and survival in colon cancer patients. Cancer Res 2000;60:2892-2897. (Pubitemid 30395812)
31. Reynolds K, Farzaneh F, Collins WP, et al.: Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994;86:1234-1238. (Pubitemid 24253699)
32. Breiman L, Friedman J, Olshen R, et al.: Classification and Regression Trees. Belmont, California: Wadsworth Internal Group. Pacific Grove, California: Advanced Books & Software; 1984.
33. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978;4:283-298. (Pubitemid 9075026)
34. Venables WN, Smith DM: and the R Development Core Team An Introduction to R: Notes on R, A. Programming Environment for Data Analysis and Graphics, v.2.0.1; Network Theory Ltd.: Bristol, U.K., 2004.
35. Findlay M, Cunningham D, Norman A, et al.: A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-616. (Pubitemid 24283097)
36. Fleischer AC, Wojcicki WE, Donnelly EF, et al.: Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med 1999;18:547-551. (Pubitemid 29350636)
37. Slavin J: Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 1995; 431-444.
38. Carmeliet P, Moons L, Luttun A, et al.: Synergism between vascular endothelial growth factor and placenta growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med 2001;7:575-583. (Pubitemid 32448325)
39. Odorisio T, Schietroma C, Zaccaria ML, et al.: Mice over-expressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002;115:2559-2567. (Pubitemid 34778073)
40. Autiero M, Waltenberger J, Communi D, et al.: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-943. (Pubitemid 36889938)
41. Salven P, Lymboussaki A, Heikkila P, et al.: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998;153:103-108. (Pubitemid 28317512)
42. Hsu C, Chen CN, Chen LT, et al.: Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors. Radiology 2005;235:509-516. (Pubitemid 40571089)
43. Shah MA, Ramanathan RK, Ilson DH, et al.: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal Junction Adenocarcinoma. J Clin Oncol 2006;24:5201-5206. (Pubitemid 46631363)
44. Kerr DJ: Targeting angiogenesis in cancer: Clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43. (Pubitemid 40812647)
45. Ross JS, Schenkein DP, Pietrusko R, et al.: Targeted therapies for cancer. Am J Clin Pathol 2004;122:598-609. (Pubitemid 39281258)